CJC-1295 no DAC + Ipamorelin is a research blend designed around two peptides studied for stimulating natural growth hormone release. Researchers are interested in this combination because it may support growth hormone signaling, recovery pathways, sleep-related hormone rhythms, and body composition research.
Scientific Information
- Full Name: CJC-1295 (no DAC) / Ipamorelin Blend
- Structure: This blend combines a short-acting GHRH analog without drug affinity complexing with a selective growth hormone secretagogue, allowing research into pulsatile growth hormone release.
Research & Potential Benefits
-
Growth Hormone Secretion Research:
CJC-1295 and ipamorelin are both studied for increasing endogenous growth hormone release through distinct receptor pathways. (Reference 1, 2) -
Pulsatile Signaling Research:
Because CJC-1295 no DAC is shorter acting, it is often discussed in research contexts involving more pulse-like hormone release patterns. (Reference 1, 3) -
Recovery & Body Composition Research:
Growth hormone secretagogue combinations are commonly studied in relation to recovery, lean mass, and body composition outcomes. (Reference 2, 3) -
Endocrine Rhythm Research:
These peptides are also of interest in research on natural hormone timing and feedback-driven release patterns. (Reference 1, 2)
References
- Teichman, S.L. et al. “Prolonged stimulation of growth hormone and insulin-like growth factor I by CJC-1295.” Journal of Clinical Endocrinology & Metabolism.
- Raun, K. et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology.
- Ionescu, M. et al. “Pulsatile secretion of growth hormone persists after CJC-1295 administration.” Journal of Clinical Endocrinology & Metabolism.
Disclaimer
For Research Use Only. Not for human consumption.
